The association between the cytochrome P450 1A1 (CYP1A1) Ile462Val polymorphism and prostate cancer risk remains inconclusive owing to the conflicting findings from previous studies.
To get a more precise estimate of the possible association, we performed the present meta-analysis. We searched the PUBMED, EMBASE, and Wanfang databases for the studies which met the inclusion criteria. The pooled odds ratio (OR) with corresponding 95 % confidence interval (95 % CI) was used to estimate the association between CYP1A1 Ile462Val polymorphism and prostate cancer risk. A total of 13 studies with 2,350 cases and 2,992 controls were included in the meta-analysis. The results indicated that there was an obvious association between CYP1A1 Ile462Val polymorphism and increased risk of prostate cancer (for Val versus Ile: OR = 1.27, 95 % CI 1.13-1.43, P < 0.001; for ValVal versus IleIle: OR = 1.51, 95 % CI 1.14-2.01, P = 0.004; for ValVal + ValIle versus IleIle: OR = 1.31, 95 % CI 1.14-1.51, P < 0.001; for ValVal versus IleIle + ValIle: OR = 1.38, 95 % CI 1.05-1.81, P = 0.020). Subgroup analyses by ethnicity suggested that CYP1A1 Ile462Val polymorphism was associated with prostate cancer risk in Asians but not in Caucasians. This meta-analysis suggests that there is an association between CYP1A1 Ile462Val polymorphism and increased risk of prostate cancer. More studies with large sample are needed to further assess the association in Caucasians.
Written by:
Han G, Ma Y, Liu P, Wei X, Zhang X, Zhu F. Are you the author?
Urology Department, The First Affiliated Hospital of Xinxiang Medical University, Healthy Road No. 88, Weihui, Henan, 453100, China.
Reference: Tumour Biol. 2013 Feb 6. Epub ahead of print.
doi: 10.1007/s13277-013-0676-4
PubMed Abstract
PMID: 23381648
UroToday.com Investigative Urology Section
